Invivyd, Inc. (IVVD)
IVVD Stock Price Chart
Explore Invivyd, Inc. interactive price chart. Choose custom timeframes to analyze IVVD price movements and trends.
IVVD Company Profile
Discover essential business fundamentals and corporate details for Invivyd, Inc. (IVVD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Aug 2021
Employees
99.00
Website
https://adagiotx.comCEO
William E. Duke Jr.
Description
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
IVVD Financial Timeline
Browse a chronological timeline of Invivyd, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $14.40m.
Earnings released on 14 May 2026
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $13.74m , missing expectations by -23.82%.
Earnings released on 5 Mar 2026
EPS came in at $0.02 surpassing the estimated -$0.06 by +133.33%, while revenue for the quarter reached $17.20m , meeting expectations.
Earnings released on 6 Nov 2025
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $13.13m , missing expectations by -15.38%.
Earnings released on 14 Aug 2025
EPS came in at -$0.12 falling short of the estimated -$0.04 by -200.00%, while revenue for the quarter reached $11.79m , missing expectations by -59.37%.
Earnings released on 15 May 2025
EPS came in at -$0.14 falling short of the estimated -$0.04 by -250.00%, while revenue for the quarter reached $11.30m , missing expectations by -35.41%.
Earnings released on 20 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.25 by +40.00%, while revenue for the quarter reached $13.82m , missing expectations by -59.88%.
Earnings released on 14 Nov 2024
EPS came in at -$0.51 falling short of the estimated -$0.33 by -54.55%, while revenue for the quarter reached $9.30m , missing expectations by -32.93%.
Earnings released on 14 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.37 by -8.11%, while revenue for the quarter reached $2.26m , missing expectations by -54.72%.
Earnings released on 9 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.51 by +25.49%.
Earnings released on 28 Mar 2024
EPS came in at -$0.67 falling short of the estimated -$0.41 by -63.41%, while revenue for the quarter reached $3.02m .
Earnings released on 9 Nov 2023
EPS came in at -$0.36 surpassing the estimated -$0.54 by +33.33%.
Earnings released on 10 Aug 2023
EPS came in at -$0.46 falling short of the estimated -$0.40 by -15.00%.
Earnings released on 11 May 2023
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%.
Earnings released on 23 Mar 2023
EPS came in at -$0.41 falling short of the estimated -$0.39 by -5.13%.
Earnings released on 10 Nov 2022
EPS came in at -$0.42 surpassing the estimated -$0.46 by +8.70%.
Earnings released on 15 Aug 2022
EPS came in at -$0.47 surpassing the estimated -$0.57 by +17.54%.
Earnings released on 13 May 2022
EPS came in at -$0.93 falling short of the estimated -$0.82 by -13.41%.
Earnings released on 30 Mar 2022
EPS came in at -$0.77 surpassing the estimated -$1.03 by +25.24%.
Earnings released on 15 Nov 2021
EPS came in at -$0.98 falling short of the estimated -$0.74 by -32.43%, while revenue for the quarter reached $3.00 , beating expectations by +33.33%.
Earnings released on 20 Sept 2021
EPS came in at -$0.18 surpassing the estimated -$0.80 by +77.50%.
Earnings released on 6 Aug 2021
EPS came in at -$0.61 .
IVVD Stock Performance
Access detailed IVVD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
